{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:17:36Z","timestamp":1794741456763,"version":"4.9.1"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31570917"],"award-info":[{"award-number":["31570917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lung cancer (LC) is the leading cause of cancer-related death worldwide due to its late diagnosis and poor outcomes. As has been found for other types of tumors, there is increasing evidence that myeloid-derived suppressor cells (MDSCs) play important roles in the promotion and progression of LC. Here, we briefly introduce the definition of MDSCs and their immunosuppressive functions. We next specifically discuss the multiple roles of MDSCs in the lung tumor microenvironment, including those in tumor growth and progression mediated by inhibiting antitumor immunity, and the associations of MDSCs with a poor prognosis and increased resistance to chemotherapy and immunotherapy. Finally, we also discuss preclinical and clinical treatment strategies targeting MDSCs, which may have the potential to enhance the efficacy of immunotherapy.<\/jats:p>","DOI":"10.1186\/s13045-020-0843-1","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T14:02:59Z","timestamp":1580479379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Myeloid-derived suppressor cells\u2014new and exciting players in lung cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Zhenzhen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanling","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-7115","authenticated-orcid":false,"given":"Wang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"issue":"6","key":"843_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"843_CR2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/path.5241","volume":"247","author":"S Milette","year":"2019","unstructured":"Milette S, Fiset PO, Walsh LA, Spicer JD, Quail DF. The innate immune architecture of lung tumors and its implication in disease progression. J Pathol. 2019;247(5):589\u2013605.","journal-title":"J Pathol"},{"key":"843_CR3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.phrs.2016.05.007","volume":"110","author":"D Adah","year":"2016","unstructured":"Adah D, Hussain M, Qin L, Qin L, Zhang J, Chen X. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacol Res. 2016;110:25\u201334.","journal-title":"Pharmacol Res"},{"key":"843_CR4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fonc.2019.00295","volume":"9","author":"M Tavakkoli","year":"2019","unstructured":"Tavakkoli M, Wilkins CR, Mones JV, Mauro MJ. A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer. Front Oncol. 2019;9:295.","journal-title":"Front Oncol"},{"issue":"10","key":"843_CR5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13(10):739\u201352.","journal-title":"Nat Rev Cancer"},{"key":"843_CR6","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"issue":"1","key":"843_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"843_CR8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/2326-6066.CIR-13-0129","volume":"2","author":"ML Ortiz","year":"2014","unstructured":"Ortiz ML, Lu L, Ramachandran I, Gabrilovich DI. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res. 2014;2(1):50\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"843_CR9","doi-asserted-by":"crossref","first-page":"e40677","DOI":"10.1371\/journal.pone.0040677","volume":"7","author":"MK Srivastava","year":"2012","unstructured":"Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012;7(7):e40677.","journal-title":"PLoS One"},{"issue":"2","key":"843_CR10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00262-015-1782-5","volume":"65","author":"S Mandruzzato","year":"2016","unstructured":"Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65(2):161\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"843_CR11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.intimp.2011.03.003","volume":"11","author":"S Ueha","year":"2011","unstructured":"Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol. 2011;11(7):783\u20138.","journal-title":"Int Immunopharmacol"},{"key":"843_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fimmu.2017.00086","volume":"8","author":"LA Elliott","year":"2017","unstructured":"Elliott LA, Doherty GA, Sheahan K, Ryan EJ. Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol. 2017;8:86.","journal-title":"Front Immunol"},{"issue":"8","key":"843_CR13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","volume":"61","author":"CA Dumitru","year":"2012","unstructured":"Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"843_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"CY Liu","year":"2010","unstructured":"Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+\/CD14(-)\/CD15+\/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"843_CR15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/rccm.201204-0636OC","volume":"186","author":"PH Feng","year":"2012","unstructured":"Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, et al. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012;186(10):1025\u201336.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"843_CR16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.lungcan.2013.06.005","volume":"81","author":"ME Heuvers","year":"2013","unstructured":"Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AM, Groen HJ, Smit EF, Hoogsteden HC, Hegmans JP, Aerts JG. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer. 2013;81(3):468\u201374.","journal-title":"Lung Cancer"},{"issue":"9","key":"843_CR17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00262-013-1450-6","volume":"62","author":"A Huang","year":"2013","unstructured":"Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14(+)HLA-DR (-\/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013;62(9):1439\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"843_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/CBM-150473","volume":"15","author":"T Tian","year":"2015","unstructured":"Tian T, Gu X, Zhang B, Liu Y, Yuan C, Shao L, Guo Y, Fan K. Increased circulating CD14(+)HLA-DR-\/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark. 2015;15(4):425\u201332.","journal-title":"Cancer Biomark"},{"issue":"2","key":"843_CR19","doi-asserted-by":"crossref","first-page":"e977164","DOI":"10.4161\/2162402X.2014.977164","volume":"4","author":"G Zhang","year":"2015","unstructured":"Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu Y, Liu C, Hou J, Zhang X. A novel subset of B7-H3(+)CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology. 2015;4(2):e977164.","journal-title":"Oncoimmunology"},{"issue":"7","key":"843_CR20","doi-asserted-by":"crossref","first-page":"e1014242","DOI":"10.1080\/2162402X.2015.1014242","volume":"4","author":"PL de Goeje","year":"2015","unstructured":"de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. Oncoimmunology. 2015;4(7):e1014242.","journal-title":"Oncoimmunology"},{"issue":"6","key":"843_CR21","doi-asserted-by":"crossref","first-page":"e1320011","DOI":"10.1080\/2162402X.2017.1320011","volume":"6","author":"J Li","year":"2017","unstructured":"Li J, Wang L, Chen X, Li L, Li Y, Ping Y, Huang L, Yue D, Zhang Z, Wang F, et al. CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017;6(6):e1320011.","journal-title":"Oncoimmunology"},{"key":"843_CR22","doi-asserted-by":"crossref","first-page":"659294","DOI":"10.1155\/2014\/659294","volume":"2014","author":"EK Vetsika","year":"2014","unstructured":"Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V, Kotsakis A. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic\/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014;2014:659294.","journal-title":"J Immunol Res"},{"issue":"8","key":"843_CR23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtho.2016.04.026","volume":"11","author":"F Koinis","year":"2016","unstructured":"Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A. Effect of first-line treatment on myeloid-derived suppressor cells\u2019 subpopulations in the peripheral blood of patients with non-small cell lung cancer. J Thorac Oncol. 2016;11(8):1263\u201372.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"843_CR24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1164\/rccm.201808-1502LE","volume":"199","author":"HR Kim","year":"2019","unstructured":"Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI. The ratio of peripheral regulatory T cells to Lox-1(+) Polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2019;199(2):243\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"843_CR25","doi-asserted-by":"crossref","first-page":"e1564505","DOI":"10.1080\/2162402X.2018.1564505","volume":"8","author":"E Limagne","year":"2019","unstructured":"Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F. Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019;8(4):e1564505.","journal-title":"Oncoimmunology"},{"key":"843_CR26","doi-asserted-by":"publisher","unstructured":"Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, et al. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. Clin Transl Oncol. 2019. https:\/\/doi.org\/10.1007\/s12094-019-02166-z.","DOI":"10.1007\/s12094-019-02166-z"},{"issue":"12","key":"843_CR27","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.3390\/ijms19123963","volume":"19","author":"Arturo Navarro-Mart\u00edn","year":"2018","unstructured":"Navarro-Martin A, Galiana IL, Berenguer Frances MA, Cacicedo J, Canas Cortes R, Comas Anton S, Padrones Sanchez S, Bolivar Cuevas S, Parry R, Guedea Edo F. Preliminary study of the effect of stereotactic body radiotherapy (SBRT) on the immune system in lung cancer patients unfit for surgery: immunophenotyping analysis. Int J Mol Sci. 2018;19(12). https:\/\/doi.org\/10.3390\/ijms19123963.","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"843_CR28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1164\/rccm.201708-1707OC","volume":"198","author":"Y Yamauchi","year":"2018","unstructured":"Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, et al. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med. 2018;198(6):777\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"843_CR29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41419-019-1837-1","volume":"10","author":"X Han","year":"2019","unstructured":"Han X, Shi H, Sun Y, Shang C, Luan T, Wang D, Zeng X, Ba X. CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18\/ERK\/STAT3. Cell Death Dis. 2019;10(8):598.","journal-title":"Cell Death Dis"},{"issue":"2","key":"843_CR30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","volume":"44","author":"V Kumar","year":"2016","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 2016;44(2):303\u201315.","journal-title":"Immunity"},{"issue":"3","key":"843_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000355126","volume":"6","author":"H Shime","year":"2014","unstructured":"Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun. 2014;6(3):293\u2013305.","journal-title":"J Innate Immun"},{"key":"843_CR32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","volume":"10","author":"A Bruno","year":"2019","unstructured":"Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. 2019;10:771.","journal-title":"Front Immunol"},{"issue":"5","key":"843_CR33","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/jcm8050736","volume":"8","author":"Chin-Chung Shu","year":"2019","unstructured":"Shu CC, Pan SW, Feng JY, Wang JY, Chan YJ, Yu CJ, Su WJ. The clinical significance of programmed death-1, regulatory T cells and myeloid derived suppressor cells in patients with nontuberculous mycobacteria-lung disease. J Clin Med. 2019;8(5).\u00a0https:\/\/doi.org\/10.3390\/jcm8050736.","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"843_CR34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4049\/jimmunol.1701069","volume":"201","author":"Y Wang","year":"2018","unstructured":"Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR, Kearney JF, Ponnazhagan S, Hsu HC, Deshane JS. Myeloid-derived suppressor cells impair B cell responses in lung cancer through IL-7 and STAT5. J Immunol. 2018;201(1):278\u201395.","journal-title":"J Immunol"},{"issue":"4","key":"843_CR35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22(4):275\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"843_CR36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"4","key":"843_CR37","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1002\/jcp.26075","volume":"233","author":"E Safarzadeh","year":"2018","unstructured":"Safarzadeh E, Orangi M, Mohammadi H, Babaie F, Baradaran B. Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis. J Cell Physiol. 2018;233(4):3024\u201336.","journal-title":"J Cell Physiol"},{"issue":"2","key":"843_CR38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1189\/jlb.4MR1116-476R","volume":"102","author":"A Sica","year":"2017","unstructured":"Sica A, Strauss L. Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. J Leukoc Biol. 2017;102(2):325\u201334.","journal-title":"J Leukoc Biol"},{"issue":"24","key":"843_CR39","doi-asserted-by":"crossref","first-page":"21123","DOI":"10.1074\/jbc.M110675200","volume":"277","author":"PC Rodriguez","year":"2002","unstructured":"Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem. 2002;277(24):21123\u20139.","journal-title":"J Biol Chem"},{"issue":"4","key":"843_CR40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2007","unstructured":"Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568\u201373.","journal-title":"Blood"},{"issue":"2","key":"843_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","volume":"75","author":"M Fletcher","year":"2015","unstructured":"Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami AA, Sanchez-Pino D, Hernandez C, Wyczechowska DD, Ochoa AC, et al. L-arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 2015;75(2):275\u201383.","journal-title":"Cancer Res"},{"issue":"12","key":"843_CR42","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.3390\/ijms19123805","volume":"19","author":"Qingjie Xue","year":"2018","unstructured":"Xue Q, Yan Y, Zhang R, Xiong H. Regulation of iNOS on immune cells and its role in diseases. Int J Mol Sci. 2018;19(12).\u00a0https:\/\/doi.org\/10.3390\/ijms19123805.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"843_CR43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molmed.2018.02.002","volume":"24","author":"A Garcia-Ortiz","year":"2018","unstructured":"Garcia-Ortiz A, Serrador JM. Nitric oxide signaling in T cell-mediated immunity. Trends Mol Med. 2018;24(4):412\u201327.","journal-title":"Trends Mol Med"},{"issue":"6","key":"843_CR44","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","volume":"184","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184(6):3106\u201316.","journal-title":"J Immunol"},{"issue":"11","key":"843_CR45","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1093\/nar\/gks066","volume":"40","author":"T Latham","year":"2012","unstructured":"Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ, Hayward L, Langridge-Smith P, Gilbert N, Ramsahoye BH. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res. 2012;40(11):4794\u2013803.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"843_CR46","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","volume":"191","author":"Z Husain","year":"2013","unstructured":"Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486\u201395.","journal-title":"J Immunol"},{"issue":"3","key":"843_CR47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","volume":"74","author":"G Liu","year":"2014","unstructured":"Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang X, Liu H, Lu Y, Liao J, Chen X, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res. 2014;74(3):727\u201337.","journal-title":"Cancer Res"},{"issue":"16","key":"843_CR48","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","volume":"70","author":"B Zhang","year":"2010","unstructured":"Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 2010;70(16):6407\u201311.","journal-title":"Cancer Res"},{"issue":"1","key":"843_CR49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121\u201344.","journal-title":"Immunol Rev"},{"issue":"7","key":"843_CR50","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","volume":"78","author":"L Li","year":"2018","unstructured":"Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78(7):1779\u201391.","journal-title":"Cancer Res"},{"issue":"3","key":"843_CR51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imm.12133","volume":"140","author":"JK Lee","year":"2013","unstructured":"Lee JK, Won C, Yi EH, Seok SH, Kim MH, Kim SJ, Chung MH, Lee HG, Ikuta K, Ye SK. Signal transducer and activator of transcription 3 (Stat3) contributes to T-cell homeostasis by regulating pro-survival Bcl-2 family genes. Immunology. 2013;140(3):288\u2013300.","journal-title":"Immunology"},{"issue":"18","key":"843_CR52","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1158\/0008-5472.CAN-07-0647","volume":"67","author":"Y Li","year":"2007","unstructured":"Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007;67(18):8494\u2013503.","journal-title":"Cancer Res"},{"issue":"4","key":"843_CR53","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.ajpath.2011.06.028","volume":"179","author":"L Wu","year":"2011","unstructured":"Wu L, Du H, Li Y, Qu P, Yan C. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol. 2011;179(4):2131\u201341.","journal-title":"Am J Pathol"},{"issue":"12","key":"843_CR54","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1021\/pr500854x","volume":"13","author":"MC Burke","year":"2014","unstructured":"Burke MC, Oei MS, Edwards NJ, Ostrand-Rosenberg S, Fenselau C. Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. J Proteome Res. 2014;13(12):5965\u201372.","journal-title":"J Proteome Res"},{"issue":"1","key":"843_CR55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-019-0772-z","volume":"12","author":"X Tian","year":"2019","unstructured":"Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12(1):84.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"843_CR56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/onc.2016.229","volume":"36","author":"Z Deng","year":"2017","unstructured":"Deng Z, Rong Y, Teng Y, Zhuang X, Samykutty A, Mu J, Zhang L, Cao P, Yan J, Miller D, et al. Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene. 2017;36(5):639\u201351.","journal-title":"Oncogene"},{"issue":"6","key":"843_CR57","doi-asserted-by":"crossref","first-page":"e1008371","DOI":"10.1080\/2162402X.2015.1008371","volume":"4","author":"K Ridder","year":"2015","unstructured":"Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sultmann H, et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology. 2015;4(6):e1008371.","journal-title":"Oncoimmunology"},{"issue":"6","key":"843_CR58","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ni1466","volume":"8","author":"H Hara","year":"2007","unstructured":"Hara H, Ishihara C, Takeuchi A, Imanishi T, Xue L, Morris SW, Inui M, Takai T, Shibuya A, Saijo S, et al. The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol. 2007;8(6):619\u201329.","journal-title":"Nat Immunol"},{"key":"843_CR59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1443.024","volume":"1143","author":"J Ruland","year":"2008","unstructured":"Ruland J. CARD9 signaling in the innate immune response. Ann N Y Acad Sci. 2008;1143:35\u201344.","journal-title":"Ann N Y Acad Sci"},{"key":"843_CR60","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3389\/fimmu.2018.01836","volume":"9","author":"RA Drummond","year":"2018","unstructured":"Drummond RA, Franco LM, Lionakis MS. Human CARD9: a critical molecule of fungal immune surveillance. Front Immunol. 2018;9:1836.","journal-title":"Front Immunol"},{"issue":"2","key":"843_CR61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41419-017-0084-6","volume":"9","author":"X Zhong","year":"2018","unstructured":"Zhong X, Chen B, Yang L, Yang Z. Molecular and physiological roles of the adaptor protein CARD9 in immunity. Cell Death Dis. 2018;9(2):52.","journal-title":"Cell Death Dis"},{"issue":"8","key":"843_CR62","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ijc.32355","volume":"145","author":"J Qu","year":"2019","unstructured":"Qu J, Liu L, Xu Q, Ren J, Xu Z, Dou H, Shen S, Hou Y, Mou Y, Wang T. CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production. Int J Cancer. 2019;145(8):2225\u201337.","journal-title":"Int J Cancer"},{"issue":"2","key":"843_CR63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cdd.2016.111","volume":"24","author":"ZH Chen","year":"2017","unstructured":"Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, Luo XQ, Chen YQ. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24(2):212\u201324.","journal-title":"Cell Death Differ"},{"issue":"1","key":"843_CR64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-016-0274-1","volume":"9","author":"S Wei","year":"2016","unstructured":"Wei S, Zhao M, Wang X, Li Y, Wang K. PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. J Hematol Oncol. 2016;9(1):44.","journal-title":"J Hematol Oncol"},{"key":"843_CR65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fimmu.2018.00473","volume":"9","author":"X Tian","year":"2018","unstructured":"Tian X, Ma J, Wang T, Tian J, Zhang Y, Mao L, Xu H, Wang S. Long non-coding RNA HOXA transcript antisense RNA myeloid-specific 1-HOXA1 axis downregulates the immunosuppressive activity of myeloid-derived suppressor cells in lung cancer. Front Immunol. 2018;9:473.","journal-title":"Front Immunol"},{"issue":"12","key":"843_CR66","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/15476286.2017.1358347","volume":"14","author":"X Zhang","year":"2017","unstructured":"Zhang X, Hamblin MH, Yin KJ. The long noncoding RNA Malat1: its physiological and pathophysiological functions. RNA Biol. 2017;14(12):1705\u201314.","journal-title":"RNA Biol"},{"issue":"3","key":"843_CR67","doi-asserted-by":"crossref","first-page":"e1003368","DOI":"10.1371\/journal.pgen.1003368","volume":"9","author":"V Tripathi","year":"2013","unstructured":"Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9(3):e1003368.","journal-title":"PLoS Genet"},{"issue":"1","key":"843_CR68","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13046-019-1237-5","volume":"38","author":"N Lin","year":"2019","unstructured":"Lin N, Yao Z, Xu M, Chen J, Lu Y, Yuan L, Zhou S, Zou X, Xu R. Long noncoding RNA MALAT1 potentiates growth and inhibits senescence by antagonizing ABI3BP in gallbladder cancer cells. J Exp Clin Cancer Res. 2019;38(1):244.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"843_CR69","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1097\/JTO.0b013e3182307eac","volume":"6","author":"LH Schmidt","year":"2011","unstructured":"Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6(12):1984\u201392.","journal-title":"J Thorac Oncol"},{"issue":"14","key":"843_CR70","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.7150\/jca.24796","volume":"9","author":"Q Zhou","year":"2018","unstructured":"Zhou Q, Tang X, Tian X, Tian J, Zhang Y, Ma J, Xu H, Wang S. LncRNA MALAT1 negatively regulates MDSCs in patients with lung cancer. J Cancer. 2018;9(14):2436\u201342.","journal-title":"J Cancer"},{"issue":"1","key":"843_CR71","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12885-018-4564-6","volume":"18","author":"X Tian","year":"2018","unstructured":"Tian X, Ma J, Wang T, Tian J, Zheng Y, Peng R, Wang Y, Zhang Y, Mao L, Xu H, et al. Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer. BMC Cancer. 2018;18(1):660.","journal-title":"BMC Cancer"},{"issue":"1","key":"843_CR72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-019-0978-2","volume":"18","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Tian X, Wang T, Xia X, Cao F, Tian J, Xu P, Ma J, Xu H, Wang S. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Mol Cancer. 2019;18(1):61.","journal-title":"Mol Cancer"},{"issue":"18","key":"843_CR73","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.7150\/jca.35205","volume":"10","author":"Y Su","year":"2019","unstructured":"Su Y, Qiu Y, Qiu Z, Qu P. MicroRNA networks regulate the differentiation, expansion and suppression function of myeloid-derived suppressor cells in tumor microenvironment. J Cancer. 2019;10(18):4350\u20136.","journal-title":"J Cancer"},{"issue":"3","key":"843_CR74","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4049\/jimmunol.1301309","volume":"192","author":"L Li","year":"2014","unstructured":"Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang CY, Zen K. MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol. 2014;192(3):1034\u201343.","journal-title":"J Immunol"},{"issue":"6","key":"843_CR75","doi-asserted-by":"crossref","first-page":"E602","DOI":"10.1002\/ijc.29151","volume":"136","author":"J Wang","year":"2015","unstructured":"Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, Ai W, Fan D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer. 2015;136(6):E602\u201313.","journal-title":"Int J Cancer"},{"issue":"3","key":"843_CR76","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4049\/jimmunol.1500209","volume":"195","author":"J Tian","year":"2015","unstructured":"Tian J, Rui K, Tang X, Ma J, Wang Y, Tian X, Zhang Y, Xu H, Lu L, Wang S. MicroRNA-9 regulates the differentiation and function of myeloid-derived suppressor cells via targeting Runx1. J Immunol. 2015;195(3):1301\u201311.","journal-title":"J Immunol"},{"issue":"1","key":"843_CR77","first-page":"123","volume":"20","author":"P Goldin-Lang","year":"2008","unstructured":"Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep. 2008;20(1):123\u20138.","journal-title":"Oncol Rep"},{"issue":"7","key":"843_CR78","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1021\/acs.nanolett.9b01785","volume":"19","author":"S Liu","year":"2019","unstructured":"Liu S, Zhang Y, Zhao X, Wang J, Di C, Zhao Y, Ji T, Cheng K, Wang Y, Chen L, et al. Tumor-specific silencing of tissue factor suppresses metastasis and prevents cancer-associated hypercoagulability. Nano Lett. 2019;19(7):4721\u201330.","journal-title":"Nano Lett"},{"issue":"1","key":"843_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms18010022","volume":"18","author":"Xiao Han","year":"2017","unstructured":"Han X, Zha H, Yang F, Guo B, Zhu B. Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells. Int J Mol Sci. 2017;18(1).\u00a0https:\/\/doi.org\/10.3390\/ijms18010022.","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"843_CR80","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI74056","volume":"124","author":"T Condamine","year":"2014","unstructured":"Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124(6):2626\u201339.","journal-title":"J Clin Invest"},{"issue":"11","key":"843_CR81","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1158\/0008-5472.CAN-15-2528","volume":"76","author":"D Peng","year":"2016","unstructured":"Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6\/STAT3 and NO\/NOTCH cross-talk signaling. Cancer Res. 2016;76(11):3156\u201365.","journal-title":"Cancer Res"},{"issue":"1","key":"843_CR82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","volume":"18","author":"L Ai","year":"2019","unstructured":"Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, Cui G, Wang Y, Guo T, Mei H, et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer. 2019;18(1):88.","journal-title":"Mol Cancer"},{"issue":"10","key":"843_CR83","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-015-1737-x","volume":"64","author":"S Scrimini","year":"2015","unstructured":"Scrimini S, Pons J, Agusti A, Clemente A, Sallan MC, Bauca JM, Soriano JB, Cosio BG, Lopez M, Crespi C, et al. Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunol Immunother. 2015;64(10):1261\u201370.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"843_CR84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlb.66.3.375","volume":"66","author":"M Colonna","year":"1999","unstructured":"Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol. 1999;66(3):375\u201381.","journal-title":"J Leukoc Biol"},{"issue":"20","key":"843_CR85","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.M111.221028","volume":"286","author":"H Cheng","year":"2011","unstructured":"Cheng H, Mohammed F, Nam G, Chen Y, Qi J, Garner LI, Allen RL, Yan J, Willcox BE, Gao GF. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3\/LIR-5\/CD85k): a myeloid inhibitory receptor involved in immune tolerance. J Biol Chem. 2011;286(20):18013\u201325.","journal-title":"J Biol Chem"},{"issue":"1","key":"843_CR86","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2007.01.013","volume":"248","author":"N Suciu-Foca","year":"2007","unstructured":"Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol. 2007;248(1):59\u201367.","journal-title":"Cell Immunol"},{"issue":"2","key":"843_CR87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830180903281185","volume":"29","author":"G Vlad","year":"2010","unstructured":"Vlad G, Chang CC, Colovai AI, Vasilescu ER, Cortesini R, Suciu-Foca N. Membrane and soluble ILT3 are critical to the generation of T suppressor cells and induction of immunological tolerance. Int Rev Immunol. 2010;29(2):119\u201332.","journal-title":"Int Rev Immunol"},{"issue":"8","key":"843_CR88","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Dejou C, Jecko D, Becquart O, et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411\u201325 e2419.","journal-title":"Cell Rep"},{"key":"843_CR89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-immunol-051116-052406","volume":"37","author":"J Linden","year":"2019","unstructured":"Linden J, Koch-Nolte F, Dahl G. Purine release, metabolism, and signaling in the inflammatory response. Annu Rev Immunol. 2019;37:325\u201347.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"843_CR90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728222.2019.1559829","volume":"23","author":"G Ghalamfarsa","year":"2019","unstructured":"Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, Yousefi M, Jadidi-Niaragh F. CD73 as a potential opportunity for cancer immunotherapy. Expert Opin Ther Targets. 2019;23(2):127\u201342.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"843_CR91","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","volume":"22","author":"MC Takenaka","year":"2019","unstructured":"Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, Gutierrez-Vazquez C, Kenison J, Tjon EC, Barroso A, et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22(5):729\u201340.","journal-title":"Nat Neurosci"},{"key":"843_CR92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.exger.2014.12.001","volume":"61","author":"S Chen","year":"2015","unstructured":"Chen S, Liu H, Su N, Zhang G, Wang L. Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1. Exp Gerontol. 2015;61:84\u201391.","journal-title":"Exp Gerontol"},{"issue":"6","key":"843_CR93","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1007\/s11033-014-3276-5","volume":"41","author":"T Wang","year":"2014","unstructured":"Wang T, Chu Z, Lin H, Jiang J, Zhou X, Liang X. Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice. Mol Biol Rep. 2014;41(6):4069\u201376.","journal-title":"Mol Biol Rep"},{"issue":"9\u201310","key":"843_CR94","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/smll.201201470","volume":"9","author":"AA Shvedova","year":"2013","unstructured":"Shvedova AA, Tkach AV, Kisin ER, Khaliullin T, Stanley S, Gutkin DW, Star A, Chen Y, Shurin GV, Kagan VE, et al. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small. 2013;9(9\u201310):1691\u20135.","journal-title":"Small"},{"issue":"8","key":"843_CR95","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-14-2376","volume":"75","author":"AA Shvedova","year":"2015","unstructured":"Shvedova AA, Kisin ER, Yanamala N, Tkach AV, Gutkin DW, Star A, Shurin GV, Kagan VE, Shurin MR. MDSC and TGFbeta are required for facilitation of tumor growth in the lungs of mice exposed to carbon nanotubes. Cancer Res. 2015;75(8):1615\u201323.","journal-title":"Cancer Res"},{"issue":"1","key":"843_CR96","doi-asserted-by":"crossref","first-page":"e1505174","DOI":"10.1080\/2162402X.2018.1505174","volume":"8","author":"M Dajon","year":"2019","unstructured":"Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, et al. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2019;8(1):e1505174.","journal-title":"Oncoimmunology"},{"issue":"10","key":"843_CR97","doi-asserted-by":"crossref","first-page":"e0164514","DOI":"10.1371\/journal.pone.0164514","volume":"11","author":"S Zhang","year":"2016","unstructured":"Zhang S, Ma X, Zhu C, Liu L, Wang G, Yuan X. The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLoS One. 2016;11(10):e0164514.","journal-title":"PLoS One"},{"issue":"5","key":"843_CR98","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-013-1396-8","volume":"62","author":"C Iclozan","year":"2013","unstructured":"Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"843_CR99","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","volume":"13","author":"PH Feng","year":"2018","unstructured":"Feng PH, Chen KY, Huang YC, Luo CS, Wu SM, Chen TT, Lee CN, Yeh CT, Chuang HC, Han CL, et al. Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2018;13(7):958\u201367.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"843_CR100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molonc.2014.08.008","volume":"9","author":"LH Hoeppner","year":"2015","unstructured":"Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, Yang P, Roden AC, Peikert T, Molina JR, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol. 2015;9(1):270\u201381.","journal-title":"Mol Oncol"},{"issue":"1","key":"843_CR101","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.molimm.2012.10.035","volume":"54","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Xu M, Li X, Jia J, Fan K, Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol. 2013;54(1):74\u201383.","journal-title":"Mol Immunol"},{"issue":"22","key":"843_CR102","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1158\/0008-5472.CAN-13-0987","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 2013;73(22):6609\u201320.","journal-title":"Cancer Res"},{"key":"843_CR103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2018.05.005","volume":"431","author":"A Li","year":"2018","unstructured":"Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, et al. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018;431:54\u201363.","journal-title":"Cancer Lett"},{"issue":"17","key":"843_CR104","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res. 2017;23(17):5187\u2013201.","journal-title":"Clin Cancer Res"},{"key":"843_CR105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 2018;11:27\u201332.","journal-title":"J Bone Oncol"},{"issue":"6","key":"843_CR106","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jtho.2019.02.004","volume":"14","author":"JW Lee","year":"2019","unstructured":"Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, et al. The combination of MEK inhibitor with Immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras\/p53-driven lung cancer. J Thorac Oncol. 2019;14(6):1046\u201360.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"843_CR107","first-page":"907","volume":"16","author":"W Liu","year":"2018","unstructured":"Liu W, Wu T-C, Hong D-M, Hu Y, Fan T, Guo W-J, Xu Q. Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells. Chin J Nat Med. 2018;16(12):907\u201315.","journal-title":"Chin J Nat Med"},{"issue":"9","key":"843_CR108","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/cas.13720","volume":"109","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Shao Q, Zhu H, Xu H, Long W, Yu B, Zhou L, Xu H, Wu Y, Su Z. Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability. Cancer Sci. 2018;109(9):2677\u201386.","journal-title":"Cancer Sci"},{"key":"843_CR109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.intimp.2016.07.035","volume":"39","author":"D Liu","year":"2016","unstructured":"Liu D, You M, Xu Y, Li F, Zhang D, Li X, Hou Y. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int Immunopharmacol. 2016;39:265\u201372.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"843_CR110","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.4049\/jimmunol.166.9.5398","volume":"166","author":"DI Gabrilovich","year":"2001","unstructured":"Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166(9):5398\u2013406.","journal-title":"J Immunol"},{"issue":"24","key":"843_CR111","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","volume":"14","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"843_CR112","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ijc.26411","volume":"131","author":"JM Lee","year":"2012","unstructured":"Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer. 2012;131(3):741\u201351.","journal-title":"Int J Cancer"},{"issue":"22","key":"843_CR113","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021\u20138.","journal-title":"Cancer Res"},{"issue":"9","key":"843_CR114","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85974","volume":"1","author":"T Courau","year":"2016","unstructured":"Courau T, Nehar-Belaid D, Florez L, Levacher B, Vazquez T, Brimaud F, Bellier B, Klatzmann D. TGF-beta and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1(9):e85974.","journal-title":"JCI Insight"},{"issue":"4","key":"843_CR115","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1000901","volume":"185","author":"MG Lechner","year":"2010","unstructured":"Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4):2273\u201384.","journal-title":"J Immunol"},{"issue":"5","key":"843_CR116","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","volume":"7","author":"S Basu","year":"2001","unstructured":"Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor. Nat Med. 2001;7(5):569\u201374.","journal-title":"Nat Med"},{"issue":"16","key":"843_CR117","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1158\/0008-5472.CAN-04-1600","volume":"64","author":"S Basu","year":"2004","unstructured":"Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor\/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004;64(16):5551\u20135.","journal-title":"Cancer Res"},{"key":"843_CR118","doi-asserted-by":"crossref","first-page":"539706","DOI":"10.1155\/2010\/539706","volume":"2010","author":"J Tilan","year":"2010","unstructured":"Tilan J, Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol. 2010;2010:539706.","journal-title":"J Oncol"},{"issue":"2","key":"843_CR119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/cancers8020025","volume":"8","author":"Takuji Tanaka","year":"2016","unstructured":"Tanaka T, Kochi T, Shirakami Y, Mori T, Kurata A, Watanabe N, Moriwaki H, Shimizu M. Cimetidine and clobenpropit attenuate inflammation-associated colorectal carcinogenesis in male ICR mice. Cancers (Basel). 2016;8(2).\u00a0https:\/\/doi.org\/10.3390\/cancers8020025.","journal-title":"Cancers"},{"issue":"5","key":"843_CR120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejps.2011.02.004","volume":"42","author":"M Kubecova","year":"2011","unstructured":"Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V. Cimetidine: an anticancer drug? Eur J Pharm Sci. 2011;42(5):439\u201344.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"843_CR121","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"843_CR122","first-page":"7584691","volume":"2017","author":"J Li","year":"2017","unstructured":"Li J, Yu S, Ying J, Shi T, Wang P. Resveratrol prevents ROS-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of AMPK\/Sirt1\/PGC-1alpha pathway. Oxidative Med Cell Longev. 2017;2017:7584691.","journal-title":"Oxidative Med Cell Longev"},{"issue":"6","key":"843_CR123","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbadis.2014.09.011","volume":"1852","author":"S Bastianetto","year":"2015","unstructured":"Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta. 2015;1852(6):1195\u2013201.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"843_CR124","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbadis.2014.10.016","volume":"1852","author":"BN Zordoky","year":"2015","unstructured":"Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta. 2015;1852(6):1155\u201377.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"843_CR125","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/nu11010143","volume":"11","author":"Margherita Springer","year":"2019","unstructured":"Springer M, Moco S. Resveratrol and its human metabolites-effects on metabolic health and obesity. Nutrients. 2019;11(1). https:\/\/doi.org\/10.3390\/nu11010143.","journal-title":"Nutrients"},{"issue":"2","key":"843_CR126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.canlet.2015.11.032","volume":"371","author":"H Gwak","year":"2016","unstructured":"Gwak H, Kim S, Dhanasekaran DN, Song YS. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 2016;371(2):347\u201353.","journal-title":"Cancer Lett"},{"key":"843_CR127","doi-asserted-by":"crossref","first-page":"257543","DOI":"10.1155\/2014\/257543","volume":"2014","author":"B Buttari","year":"2014","unstructured":"Buttari B, Profumo E, Segoni L, D'Arcangelo D, Rossi S, Facchiano F, Saso L, Businaro R, Iuliano L, Rigano R. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. Oxidative Med Cell Longev. 2014;2014:257543.","journal-title":"Oxidative Med Cell Longev"},{"issue":"6","key":"843_CR128","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1124\/mol.107.038984","volume":"72","author":"NP Singh","year":"2007","unstructured":"Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3,5,4\u2032-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol. 2007;72(6):1508\u201321.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"843_CR129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/mt.2015.165","volume":"24","author":"Y Lu","year":"2016","unstructured":"Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, Xiang G, Huang L. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther. 2016;24(2):364\u201374.","journal-title":"Mol Ther"},{"issue":"6","key":"843_CR130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/CBM-140423","volume":"14","author":"C Liao","year":"2014","unstructured":"Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y, Bai L. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark. 2014;14(6):469\u201381.","journal-title":"Cancer Biomark"},{"issue":"3","key":"843_CR131","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/epi.15.118","volume":"8","author":"L Shen","year":"2016","unstructured":"Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. 2016;8(3):415\u201328.","journal-title":"Epigenomics"},{"issue":"1","key":"843_CR132","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17\u201333.","journal-title":"Cell"},{"issue":"5","key":"843_CR133","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdv072","volume":"26","author":"GR Blumenschein Jr","year":"2015","unstructured":"Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, et al. A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger. Ann Oncol. 2015;26(5):894\u2013901.","journal-title":"Ann Oncol"},{"issue":"10","key":"843_CR134","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/JTO.0b013e3181e8b3a3","volume":"5","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5(10):1630\u20136.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"843_CR135","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2017.21","volume":"31","author":"EA Eksioglu","year":"2017","unstructured":"Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172\u201380.","journal-title":"Leukemia"},{"issue":"1","key":"843_CR136","first-page":"3","volume":"11","author":"MR Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11(1):3\u201323.","journal-title":"Avicenna J Med Biotechnol"},{"key":"843_CR137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24.","journal-title":"Biomark Res"},{"key":"843_CR138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","volume":"47","author":"L Fultang","year":"2019","unstructured":"Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C, et al. MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019;47:235\u201346.","journal-title":"EBioMedicine"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-0843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-020-0843-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-0843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:25:40Z","timestamp":1722363940000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-0843-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-0843-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is not applicable for this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}